SCHEMBL12020100

SCHEMBL12020100

CCc1ncc(N)nc1C#N

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 3/20 0.34
FEN1 P39748 3/20 0.34
HSD17B10 Q99714 5/20 0.34
KDM4E B2RXH2 5/20 0.34
MAPK1 P28482 4/20 0.34
ALDH1A1 P00352 2/20 0.34
TSHR P16473 2/20 0.34
GAA P10253 2/20 0.33
PIK3CD O00329 1/20 0.33
PKM P14618 1/20 0.33
KDM5A P29375 1/20 0.32
POLB P06746 1/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23713545 0.85 GABRP (0.39) ALOX5APFEN1HSD17B10KDM4EMAPK1
SCHEMBL23638023 0.84 ALDH1A1 (0.42) ALOX5APFEN1HSD17B10KDM4EMAPK1
SCHEMBL13082572 0.79 PDE10A (0.32) MAPK1KDM5AMEN1HTTKMT2A
SCHEMBL28750598 0.76 GABRP (0.41) FEN1ALDH1A1GABRPGABRDGABRA1
SCHEMBL11032347 0.76 PIK3CD (0.43) ALOX5APFEN1KDM4EALDH1A1GAA
SCHEMBL13082147 0.75 CYP1A2 (0.34)
SCHEMBL15382040 0.75 ALOX5AP (0.36) ALOX5APFEN1HSD17B10KDM4EPIK3CD
SCHEMBL7781784 0.74 USP8 (0.40) ALOX5APFEN1PIK3CDHTTCSNK1A1
SCHEMBL6405350 0.74 NOS3 (0.36) ALDH1A1GABRPGABRDGABRA1GABRB1
SCHEMBL12020149 0.72 NOS3 (0.39) GAAGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3848370-B1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2025-05-07 EP disclosed
CN-115448916-A TYK2 inhibitor and application thereof 林伯士拉克许米公司 2022-12-09 CN disclosed
CN-109952303-B TYK2 inhibitor and application thereof 林伯士拉克许米公司 2022-10-21 CN disclosed
EP-3526222-B1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI INC (US) 2022-08-17 EP disclosed
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-10 US disclosed
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-10 US disclosed
US-11220508-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2022-01-11 US disclosed
US-11220508-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2022-01-11 US disclosed
US-11174265-B2 2021-11-16 US disclosed
US-11174265-B2 2021-11-16 US disclosed
EP-3526222-A1 TYK2 INHIBITORS AND USES THEREOF Nimbus Lakshmi, Inc. (US) 2019-08-21 EP disclosed
CN-109952303-A TYK2 inhibitor and application thereof 林伯士拉克许米公司 2019-06-28 CN disclosed
US-10323036-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2019-06-18 US disclosed
US-10323036-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2019-06-18 US disclosed
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-07 US disclosed
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-07 US disclosed
WO-2018071794-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2018-04-19 WO disclosed
WO-2018071794-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2018-04-19 WO disclosed
US-20120245162-A1 OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-27 US disclosed
US-20120220561-A1 OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11220508-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 ALOX5AP 3531/4885FEN1 2653/4885HSD17B10 2692/4885
US-10323036-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 ALOX5AP 3531/4885FEN1 2653/4885HSD17B10 2692/4885
US-20120245162-A1 OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION LTB4R, LTC4S, LTB4R2 ALOX5AP 17/4885FEN1 3181/4885HSD17B10 631/4885
US-11174265-B2 TYK2, JAK2, JAK1 ALOX5AP 3585/4885FEN1 2751/4885HSD17B10 2324/4885
US-20120220561-A1 OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION LTB4R, LTC4S, LTB4R2 ALOX5AP 17/4885FEN1 3090/4885HSD17B10 685/4885
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 ALOX5AP 3531/4885FEN1 2653/4885HSD17B10 2692/4885
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 ALOX5AP 3531/4885FEN1 2653/4885HSD17B10 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.